Aspergillus Fumigatus Infection
Conditions
Brief summary
During a two year prospective study onpatients from department's hospitals and centralized by the pneumology department Nantes CH,all respiratory clinical samples will be cultivated for Aspergillus isolation (2900Aspergillusisolates) as standard care. The azole susceptibility pattern of isolates will be determined to itraconazole, voriconazole by subculture on azole- enriched medium at 35°c as primary screen and resistance confirmed by EUCAST Reference metho.In parallel, the relevance of detecting resistance (TR34 and TR46) directly in culture-negative BAL respiratory samples by a qPCR method will be studied in an attempt to reach a greater exhaustiveness of the resistance phenomeno. In case of azole-resistant isolate,patient data such as the underlying disease,date and site of Aspergillus isolation,disease classification,previous azole drug exposure,and home and work geographic allocation,occupation of the patient will be collecte. For all other aspergillus occurrences, underlying disease, previous azole drug exposure,home and work location of the patient will be collected in an attempt to identify risk factor.
Interventions
OTHERNo intervention
No intervention excepted data collection
Sponsors
Nantes University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patient over 18 years of age * Patient who has given his or her consent to participate in the study * Patient affiliated to a social security scheme * Patient with a respiratory sample taken between 2020 and 2023 for the retrospective cohort and from 2024 for the prospective cohort in which Aspergillus has been isolated * Patients living in the Loire Atlantique and Vendée regions
Exclusion criteria
* Patient under guardianship or legal protection * Patient of no fixed adress
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Environmental risk factors | 24 months | Identify the "macro" environmental risk factors for acquiring azole-resistant aspergillus. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Describe the management and evolution of resistant | 48 months | Clinical information from each additional patient visit and presence or absence of resistant Aspergillus in home samples. |
| Risk factors | 48 months | Identify individual risk factors linked to the immediate environment in the patient's home, drug management, between cases and matched controls, etc.. |
Countries
France
Contacts
CONTACTFrançois-Xavier Blanc, PUPH
Outcome results
None listed